Brief: Renalytix Announces Collaboration With Tempus To Advance Intelligent Risk Assessment In Diabetic Kidney Disease
Sept 15 (Reuters) - Renalytix PLC RENX.L: RENALYTIX ANNOUNCES COLLABORATION WITH TEMPUS TO ADVANCE INTELLIGENT RISK ASSESSMENT IN DIABETIC KIDNEY DISEASE Source text: ID:nPnbSn716a Further company coverage: RENX.L ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Tempus AI
See all newsU.S. STOCKS ON THE MOVE-Tempus AI, Choice Hotels, Palantir
Tempus AI rises after surprise quarterly profit
Tempus AI Q3 revenue slightly beats estimates; raises guidance
Brief: Tempus Receives Ivdr Certification For Xr Rna Sequencing For Solid Tumor Profiling
Brief: Tempus Expands Strategic Collaboration With Bristol Myers Squibb